5′-NUCLEOTIDASE – Talk Bio

Actionable Insights Powered by AI

I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig

4 months ago talkbio0Tagged 5'-NUCLEOTIDASE, Antibodies, Antibodies, Bispecific, Givastomig, I-Mab, Immunotherapy for cancer, metastatic gastric cancers, pipeline, reshuffle, Uliledlimab

I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers

I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space

4 months ago talkbio0Tagged 5'-NUCLEOTIDASE, biotech, development aspects, I-Mab, sanofi, Strategic Options

I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development